Target intelligence / Profile preview

Cerebellar degeneration-related protein 1 antisense RNA (CDR1-AS)

Target
CDR1-AS
Molecular classification
Non-coding RNA, Circular RNA, Other
01

Overview

Cerebellar degeneration-related protein 1 antisense RNA (CDR1-AS), also widely known as ciRS-7, is a highly conserved, brain-abundant circular RNA (circRNA) that acts as a natural "super sponge" for microRNA-7 (miR-7). It contains over 70 binding sites for miR-7, thereby sequestering this microRNA and preventing it from suppressing its target mRNAs, which are involved in critical pathways like EGFR/RAF1 and PI3K/AKT. Consequently, dysregulation of CDR1-AS is heavily implicated in various human pathologies.

In oncology, CDR1-AS is frequently overexpressed and functions as an oncogene, promoting cell proliferation, invasion, and metastasis, as well as contributing to chemoresistance in solid tumors such as colorectal, lung, and breast cancers. Conversely, its downregulation is associated with neurodegenerative disorders like Alzheimer's disease, where its loss leads to elevated miR-7 levels and subsequent downregulation of protective target genes. While no FDA-approved drugs currently target CDR1-AS, it represents a highly promising therapeutic target and diagnostic biomarker. Preclinical strategies under investigation include the use of antisense oligonucleotides (ASOs), small interfering RNAs (siRNAs), and CRISPR/Cas9 systems to modulate its expression and restore normal microRNA regulatory networks.

Other names
CDR1asciRS-7Cerebellar degeneration-related protein 1 antisense transcriptCDR1NATCIRS7Circular RNA sponge for miR-7
02

Mechanism of action

Antisense knockdown or RNA interference to inhibit microRNA sponging activity

03

Biological functions

MicroRNA spongingGene expression regulationCell proliferationApoptosisSynaptic transmission
04

Disease associations

CancerNeurodegenerative diseaseCardiovascular diseaseDiabetes mellitus
05

Safety considerations

Off-target effects of oligonucleotide therapeuticsNeurological side effects due to high expression and functional importance of CDR1-AS in the brainDelivery challenges to the central nervous system and tumor tissues
06

Biomarkers

CDR1-AS expression levelciRS-7 expression levelmiR-7 expression level

Beyond the preview

Go deeper on Cerebellar degeneration-related protein 1 antisense RNA (CDR1-AS).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cerebellar degeneration-related protein 1 antisense RNA (CDR1-AS).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call